Condition: Fabry Disease · Sponsor: Chiesi Farmaceutici S.p.A.
The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.
This description comes directly from the study's public registry record.
Chiesi Clinical Trial · +3905212791 · clinicaltrials_info@chiesi.com
Always discuss trial participation with your own doctor first.
| Fukuoka University Chikushi Hospital | Chikushino-shi, Fukuoka, Japan | Withdrawn |
| Tohoku University Hospital | Sendai, Miyagi, Japan | Recruiting |
| University of the Ryukyu Hospital | Nishihara, Okinawa, Japan | Recruiting |
| Osaka University Hospital | Suita, Osaka, Japan | Recruiting |
| Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo | Bunkyo-ku, Tokyo, Japan | Recruiting |
| Tokyo Jikei University Hospital | Minato-ku, Tokyo, Japan | Recruiting |
| Keio University Hospital | Shinjuku-ku, Tokyo, Japan | Recruiting |
| Asahikawa Medical University Hospital | Asahikawa, Japan | Recruiting |
| Niigata University Medical & Dental Hospital | Niigata, Japan | Recruiting |
| National Hospital Organization Okayama Medical Center | Okayama, Japan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05710692